Literature DB >> 17464504

High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles.

Kathleen A Houtchens1, Robert J Nichols, Martha B Ladner, Hannah E Boal, Cristina Sollars, Daniel E Geraghty, Lee M Davis, Peter Parham, Elizabeth A Trachtenberg.   

Abstract

The killer cell immunoglobulin-like receptors (KIR) interact with major histocompatibility complex (MHC) class I ligands to regulate the functions of natural killer cells and T cells. Like human leukocyte antigens class I, human KIR are highly variable and correlated with infection, autoimmunity, pregnancy syndromes, and transplantation outcome. Limiting the scope of KIR analysis is the low resolution, sensitivity, and speed of the established methods of KIR typing. In this study, we describe a first-generation single nucleotide polymorphism (SNP)-based method for typing the 17 human KIR genes and pseudogenes that uses analysis by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. It is a high-throughput method that requires minute amounts of genomic DNA for discrimination of KIR genes with some allelic resolution. A study of 233 individuals shows that the results obtained by the SNP-based KIR/MALDI-TOF method are consistent with those obtained with the established sequence-specific oligonucleotide probe or sequence-specific polymerase chain reaction methods. The added sensitivity of the KIR/MALDI-TOF method allowed putative novel alleles of the KIR2DL1, KIR3DL1, KIR2DS5, and KIR2DL5 genes to be identified. Sequencing the KIR2DL5 variant proved it was a newly discovered allele, one that appears associated with Hispanic and Native American populations. This KIR/MALDI-TOF method of KIR typing should facilitate population and disease-association studies that improve knowledge of the immunological functions of KIR-MHC class I interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464504      PMCID: PMC2881672          DOI: 10.1007/s00251-007-0222-x

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  29 in total

1.  Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires.

Authors:  K A Crum; S E Logue; M D Curran; D Middleton
Journal:  Tissue Antigens       Date:  2000-10

2.  KIR2DL5, a novel killer-cell receptor with a D0-D2 configuration of Ig-like domains.

Authors:  C Vilches; R Rajalingam; M Uhrberg; C M Gardiner; N T Young; P Parham
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

3.  Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103.

Authors:  A Selvakumar; U Steffens; N Palanisamy; R S Chaganti; B Dupont
Journal:  Tissue Antigens       Date:  1997-06

Review 4.  The killer cell inhibitory receptor genomic region on human chromosome 19q13.4.

Authors:  B Dupont; A Selvakumar; U Steffens
Journal:  Tissue Antigens       Date:  1997-06

Review 5.  Polymorphism and domain variability of human killer cell inhibitory receptors.

Authors:  A Selvakumar; U Steffens; B Dupont
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

Review 6.  Killer cell receptors: keeping pace with MHC class I evolution.

Authors:  N M Valiante; K Lienert; H G Shilling; B J Smits; P Parham
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

7.  Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype.

Authors:  Heather G Shilling; Lisbeth A Guethlein; Nathalie W Cheng; Clair M Gardiner; Roberto Rodriguez; Dolly Tyan; Peter Parham
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

8.  Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination.

Authors:  C S Witt; C Dewing; D C Sayer; M Uhrberg; P Parham; F T Christiansen
Journal:  Transplantation       Date:  1999-12-15       Impact factor: 4.939

9.  Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis.

Authors:  George W Nelson; Maureen P Martin; Dafna Gladman; Judith Wade; John Trowsdale; Mary Carrington
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

10.  Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.

Authors:  Susan E Hiby; James J Walker; Kevin M O'shaughnessy; Christopher W G Redman; Mary Carrington; John Trowsdale; Ashley Moffett
Journal:  J Exp Med       Date:  2004-10-11       Impact factor: 14.307

View more
  17 in total

1.  The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia.

Authors:  Adam J de Smith; Kyle M Walsh; Martha B Ladner; Siming Zhang; Carmen Xiao; Franziska Cohen; Theodore B Moore; Anand P Chokkalingam; Catherine Metayer; Patricia A Buffler; Elizabeth A Trachtenberg; Joseph L Wiemels
Journal:  Blood       Date:  2014-02-11       Impact factor: 22.113

2.  Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Daniel J Weisdorf; Lisbeth A Guethlein; John P Klein; Tao Wang; Chap T Le; Steven G E Marsh; Daniel Geraghty; Stephen Spellman; Michael D Haagenson; Martha Ladner; Elizabeth Trachtenberg; Peter Parham; Jeffrey S Miller
Journal:  Blood       Date:  2010-06-25       Impact factor: 22.113

3.  Characterization of rhesus macaque KIR genotypes and haplotypes.

Authors:  Philip H Kruse; Cornelia Rosner; Lutz Walter
Journal:  Immunogenetics       Date:  2010-03-02       Impact factor: 2.846

4.  Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype.

Authors:  Marcie Tomblyn; Jo-Anne H Young; Michael D Haagenson; John P Klein; Elizabeth A Trachtenberg; Jan Storek; Stephen R Spellman; Sarah Cooley; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-01       Impact factor: 5.742

5.  KIR Donor Selection: Feasibility in Identifying better Donors.

Authors:  Daniel Weisdorf; Sarah Cooley; Tao Wang; Elizabeth Trachtenberg; Michael D Haagenson; Cynthia Vierra-Green; Stephen Spellman; Ashley Spahn; Jenny Vogel; Hati Kobusingye; Todd Fehninger; Ann Woolfrey; Steven Devine; Maureen Ross; Edmund K Waller; Ronald Sobecks; Peter Parham; Lisbeth A Guethlein; Steven G E Marsh; Jeffrey Miller
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-24       Impact factor: 5.742

6.  The HLA-B/-C haplotype block contains major determinants for host control of HIV.

Authors:  E Trachtenberg; T Bhattacharya; M Ladner; J Phair; H Erlich; S Wolinsky
Journal:  Genes Immun       Date:  2009-08-20       Impact factor: 2.676

7.  Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand.

Authors:  Jill A Hollenbach; Martha B Ladner; Koy Saeteurn; Kent D Taylor; Ling Mei; Talin Haritunians; Dermot P B McGovern; Henry A Erlich; Jerome I Rotter; Elizabeth A Trachtenberg
Journal:  Immunogenetics       Date:  2009-09-30       Impact factor: 2.846

8.  Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Daniel J Weisdorf; Lisbeth A Guethlein; John P Klein; Tao Wang; Steven G E Marsh; Stephen Spellman; Michael D Haagenson; Koy Saeturn; Martha Ladner; Elizabeth Trachtenberg; Peter Parham; Jeffrey S Miller
Journal:  J Immunol       Date:  2014-04-18       Impact factor: 5.422

9.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Elizabeth Trachtenberg; Tracy L Bergemann; Koy Saeteurn; John Klein; Chap T Le; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

10.  Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.

Authors:  Veronika Bachanova; Daniel J Weisdorf; Tao Wang; Steven G E Marsh; Elizabeth Trachtenberg; Michael D Haagenson; Stephen R Spellman; Martha Ladner; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller; Sarah A Cooley
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.